Cargando…

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'

Detalles Bibliográficos
Autores principales:	Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Vastesaeger, Nathan, Geldhof, Anja, De Keyser, Filip
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794496/ https://www.ncbi.nlm.nih.gov/pubmed/17049071 http://dx.doi.org/10.1186/ar2044

Ejemplares similares

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
por: Vander Cruyssen, Bert, et al.
Publicado: (2005)

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
por: Cruyssen, Bert Vander, et al.
Publicado: (2006)

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study
por: De Mits, Sophie, et al.
Publicado: (2016)

Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?
por: Aletaha, Daniel
Publicado: (2006)

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study
por: Durez, Patrick, et al.
Publicado: (2022)

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’
por: Vastesaeger, Nathan, et al.
Publicado: (2015)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays
por: Vander Cruyssen, Bert, et al.
Publicado: (2006)

Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification
por: Verbruggen, Gust, et al.
Publicado: (2011)

Morbid anatomy of ‘erosive osteoarthritis’ of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected joints
por: Verbruggen, Gust, et al.
Publicado: (2009)

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
por: Keyser, Filip De
Publicado: (2011)

The Good Physician
Publicado: (1864)

The Good Physician
Publicado: (1868)

The Good Physician
Publicado: (1880)

The Good Physician
Publicado: (1878)

The Good Physician
Publicado: (1856)

Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques
por: Put, Stéphanie, et al.
Publicado: (2014)

Commentary: One is as good as three
por: Athanasuleas, Constantine L.
Publicado: (2021)

Commentary: It looks good, but will it last?
por: Eikelboom, Rachel, et al.
Publicado: (2020)

A commentary on theory of mind
por: Shatz, Marilyn
Publicado: (2015)

Commentary: The enemy of good is perfect, but please define good and perfect
por: Worku, Berhane, et al.
Publicado: (2020)

THE TRAINING OF GOOD PHYSICIANS
Publicado: (1970)

Nature, the Good Physician
por: Macpherson, J. D.
Publicado: (1907)

Commentary: Good surgery gets good results: Not so good if your patient is anemic
por: Kramer, Robert S.
Publicado: (2021)

Commentary: If more is no good, then less is more
por: Alsoufi, Bahaaldin, et al.
Publicado: (2020)

Commentary: Devil is in the details…and good judgment!
por: Kumar, T.K. Susheel, et al.
Publicado: (2020)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis
por: Janssens, Xavier, et al.
Publicado: (2016)

Changes in rheumatoid factor reflect the inflammatory response (CRP and ESR) to infliximab treatment
por: De Rycke, L, et al.
Publicado: (2003)

Editorial: Risk factors for Rheumatoid Arthritis and pre-Rheumatoid Arthritis
por: Sapart, Emillie, et al.
Publicado: (2022)

Commentary: Mind-Wandering Changes in Dysphoria
por: Fell, Juergen, et al.
Publicado: (2021)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
por: Verschueren, Patrick, et al.
Publicado: (2015)

Radiological sacroiliitis is linked with CARD15 gene polymorphisms in patients with Crohn's disease
por: Cruyssen, B Vander, et al.
Publicado: (2004)

Some Reflections on Being Good, on not Being Good and on Just Being
por: Crane, Rebecca S.
Publicado: (2014)

Commentary on the MID3 Good Practices Paper
por: Manolis, Efthymios, et al.
Publicado: (2017)

Commentary: If it looks too good to be true, it probably is
por: Sellke, Frank W.
Publicado: (2021)

Commentary: Too much of a good thing
por: Greenberg, Jason W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i99e2vhipj9nlpt3p7un9ukfmb